Dr. Martin Pan from Biogen discusses how it is critical that current research methods and health-related data systems are evaluated for their ability to increase our understanding of Alzheimer’s disease across the spectrum of the disease. The ROADMAP project therefore first evaluates appropriate outcome measures based on existing data, which will later inform a second phase including prospective data generation. Through this process, trial and observational study design decisions can be properly informed, enhancing health care systems to evaluate new interventions as they become available.
Dr. Martin Pan is a physician specialised in Clinical Pharmacology. He is currently working in the European Medical Department of Biogen and coordinates efforts for the Innovative Medicines Initiative (IMI) and real world data in Alzheimer’s disease. He has over 16 years of relevant clinical research experience in different positions in clinical practice, industrial early clinical development/experimental medicine and medical affairs in Neuroscience (Alzheimer's disease and multiple sclerosis) and Infectious Diseases (neglected tropical diseases) at the headquarters of GlaxoSmithKline, Otsuka and Lundbeck.